SCHEMBL1749264

SCHEMBL1749264

CNc1ccc(N2CC[C@@H](N(C)C)C2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 2/20 0.48
FPR2 P25090 2/20 0.48
PIK3CD O00329 5/20 0.43
CSF1R P07333 5/20 0.43
CDK4 P11802 5/20 0.43
CDK6 Q00534 5/20 0.43
TNIK Q9UKE5 1/20 0.41
CCNK O75909 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK7 P50613 1/20 0.41
CDK9 P50750 1/20 0.41
CCNH P51946 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
MCHR1 Q99705 2/20 0.39
CHEK2 O96017 3/20 0.38
WDR5 P61964 2/20 0.38
LCK P06239 2/20 0.37
KDR P35968 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749267 1.00 FPR1 (0.48) FPR1FPR2PIK3CDCSF1RCDK4
SCHEMBL27959375 0.85 EML4 (0.48) FPR1FPR2CSF1RCDK4CDK6
SCHEMBL28021938 0.85 EML4 (0.48) FPR1FPR2CSF1RCDK4CDK6
SCHEMBL1749511 0.85 FPR1 (0.44) FPR1FPR2MCHR1NPY2R
SCHEMBL14450220 0.82 FPR1 (0.43) FPR1FPR2PIK3CDCSF1RCDK4
SCHEMBL1750831 0.81 NPY2R (0.42) FPR1FPR2NPY2RJAK2JAK3
SCHEMBL4259153 0.81 ALDH1A1 (0.48) FPR1FPR2PIK3CDCSF1RCDK4
SCHEMBL22164691 0.81 ALDH1A1 (0.48) FPR1FPR2PIK3CDCSF1RCDK4
SCHEMBL189139 0.81 ALDH1A1 (0.48) FPR1FPR2PIK3CDCSF1RCDK4
SCHEMBL10203188 0.78 FPR1 (0.41) FPR1FPR2CHEK2WDR5LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed
EP-1597228-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-23 EP disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed
WO-2004072025-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 FPR1 463/4885FPR2 841/4885PIK3CD 4091/4885
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 FPR1 586/4885FPR2 782/4885PIK3CD 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.